Cargando…
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Autores principales: | Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David, Mccarten, Kathleen, Horton, Terzah, Cho, Steve, Wu, Yue, Punnett, Angela, Dave, Hema, Henderson, Tara O., Hoppe, Bradford S., Charpentier, Ann-Marie, Keller, Frank G., Kelly, Kara M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621504/ http://dx.doi.org/10.1097/01.HS9.0000890916.12776.84 |
Ejemplares similares
-
P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
por: Flerlage, Jamie E., et al.
Publicado: (2022) -
P090: Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization
por: Seelisch, Jennifer, et al.
Publicado: (2022) -
P088: Case series of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Tanzania. A common entity in East Africa?
por: Kahakwa, Atukuzwe, et al.
Publicado: (2022) -
P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study
por: Vinti, Luciana, et al.
Publicado: (2022) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)